Rinaploem Sustained Release Tablets 10/5/1000 mg (Empagliflozin, Linagliptin, Metformin Hydrochloride)
Empagliflozin 10mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
MFDS item code 202502302 · Approved 2025.09.03
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes when used in conjunction with empagliflozin, linagliptin, and metformin. It is effective for blood sugar management when used alongside dietary control and exercise therapy, contributing to the stable maintenance of patients' blood sugar levels.
For antidiabetic therapy, the recommended dose of this medicine is 1 tablet once daily with a meal in patients receiving 10mg of empagliflozin, 5mg of linagliptin, and 1000mg of metformin hydrochloride. This medicine should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin hydrochloride. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another antihyperglycemic agent. Because changes may lead to changes in glycemic control, any change in treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dosage adjusted as appropriate. To maintain its extended-release properties, this medicine must be swallowed whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If the patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special Populations Patients with Renal Impairment As the efficacy and safety of this medicine depend on renal function and dosage adjustment according to renal function is required, assessment of renal function before and periodically during treatment with this medicine is recommended. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months.
This medication can cause a rare adverse effect called lactic acidosis; if this symptom occurs, immediate medical attention should be sought. This medication should not be administered to certain patients. For example, it can be dangerous for those allergic to any of its components, patients with type 1 diabetes, patients with severely impaired kidney function, patients undergoing dialysis, and patients in severe infection or shock states. Patients scheduled to undergo examinations using iodine contrast agents should discontinue this medication for a certain period before and after the examination and should only resume taking it after confirming normal kidney function. Patients undergoing surgery should stop taking this medication 48 hours prior to the surgery and resume only after confirming normal kidney function post-surgery. While taking this medication, kidney function tests should be periodically conducted, and if kidney function deteriorates, the medication should be discontinued. Patients with heart failure or a history of pancreatitis should use this medication cautiously, and if symptoms of acute pancreatitis occur, they should stop taking it immediately and consult a physician. This medication may cause hypoglycemia; therefore, caution is necessary regarding hypoglycemic symptoms, especially when taking antidiabetic agents like insulin or sulfonylureas, and medication dosages may need adjustment. This medication can increase the risk of urinary infections and genital fungal infections; hence, if any signs of infection appear, immediate treatment should be pursued. Additionally, caution is necessary during dehydration, severe diarrhea, or vomiting due to the risk of adverse effects from fluid loss, and in such cases, medication can be temporarily suspended. Elderly patients, particularly those over 75 years of age, require extra caution due to an increased risk of fluid loss and low blood pressure. This medication is not recommended for patients with impaired liver function or those who consume excessive alcohol. A skin condition called bullous pemphigoid may occur rarely; if any blisters or rashes develop, the physician should be informed immediately. While taking this medication, do not crush, chew, or break the tablets; take them whole, and it is normal for the coating of the tablet to appear in the stool. When driving or operating machinery, caution is required due to the risk of hypoglycemic symptoms. Finally, it is important to undergo regular blood tests and consistently monitor health status under a physician's guidance while taking this medication.
Lactic acidosis, ketoacidosis, coma, diabetic ketoacidosis, urinary tract infection, pyelonephritis, urosepsis, vulvovaginitis, balanitis, allergic reaction, hypoglycemia, thirst, cough, constipation, pancreatitis, oral ulcer, itching, rash, vesicular dermatitis, rhabdomyolysis, decreased fluid volume, increased urination, urinary difficulty, interstitial nephritis, increased amylase, increased lipase, increased hematocrit, increased serum lipids, vitamin B12 deficiency, taste impairment, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, erythema, urticaria, upper abdominal pain, enterocolitis, intestinal obstruction, gastritis, herpes zoster, cystitis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, abdominal pain, gastrointestinal disturbances, irritable bowel syndrome, burning mouth syndrome, colitis, abdominal discomfort, dysphagia, gastric ulcer, gum bleeding, hemorrhoids, lower abdominal pain, diarrhea, gastritis, acute pyelonephritis, leukoplakia, rhinitis, soft tissue infection, pharyngitis, scrub typhus, periodontitis, tonsillitis, laryngitis, viral upper respiratory infection, tonsillitis, hypercholesterolemia, malnutrition, hyponatremia, drowsiness, muscle weakness, chest discomfort, oropharyngeal pain, speech disorder, allergic rhinitis, exercise-induced dyspnea, wet cough, runny nose, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased blood triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased potassium in blood, increased creatinine in blood, increased creatine phosphokinase in blood, androgenetic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, rib fracture, laceration, palpitations, tachycardia, atherosclerosis, deep vein thrombosis, diabetic vascular complications, peripheral arterial obstructive disease, goiter, hypothyroidism, thyroid nodule, otalgia, orthostatic dizziness, dizziness, anemia, lymphadenopathy, vulvar pruritus, genital pruritus, dyslipidemia, obesity, dermoid cyst, seborrheic dermatitis, atopic dermatitis, nummular eczema, heat rash, sebaceous gland hyperplasia, lumbar spinal canal stenosis, myalgia, limb pain, musculoskeletal thoracic pain, cervical stenosis, fibromyalgia, flank pain, fracture pain, muscle weakness, osteoarthritis, astigmatism, cataract, allergic conjunctivitis, blurred vision, corneal erosion, macular fibrosis, ocular discomfort, ocular congestion, pathological myopia, retinal deposits, retinal vein occlusion, macular retinal detachment, eyelid swelling, visual impairment, vitreous floaters, vitreous hemorrhage, nosebleed, exertional dyspnea, wet cough, residual sputum, nosebleed, benign prostatic hyperplasia, erectile dysfunction, atrophic vaginitis, cervical dysplasia, vaginal discharge, hypothyroidism, thyroid nodule
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius to preserve its effectiveness.
White and light yellow biconvex oval sustained release film-coated tablets
Bottle packaging - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 12.5mg · Linagliptin Micronized 2.5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Empagliflozin 25mg · Linagliptin Micronized 5mg +1 more
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.